Why the study?
Do vitamin K antagonists (VKAs) provide better safety and efficacy compared to direct oral anticoagulants (DOACs) in patients with mechanical heart valves and rheumatic mitral stenosis?
Do vitamin K antagonists (VKAs) provide better safety and efficacy compared to direct oral anticoagulants (DOACs) in patients with mechanical heart valves and rheumatic mitral stenosis?
VKAs remain the only oral anticoagulants with established safety and efficacy for patients with mechanical heart valves and rheumatic mitral stenosis, despite the growing use of DOACs.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: